EPRONTIA
Eprontia (topiramate) is indicated for the treatment of epilepsy and the preventive treatment of migraine. In epilepsy, it is used as initial monotherapy or adjunctive therapy for partial-onset and primary generalized tonic-clonic seizures in patients aged two years and older. It is also approved as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome and for migraine prevention in patients 12 years of age and older.
How EPRONTIA Works
While the precise mechanism of action is unknown, topiramate is thought to exert its effects through four properties identified in preclinical studies. It blocks voltage-dependent sodium channels and enhances the activity of the inhibitory neurotransmitter gamma-aminobutyrate at GABA-A receptors. Additionally, the drug antagonizes AMPA/kainate glutamate receptors and inhibits carbonic anhydrase enzymes, specifically isozymes II and IV.
Details
- Status
- Prescription
- First Approved
- 2021-11-05
- Routes
- ORAL
- Dosage Forms
- SOLUTION
EPRONTIA Approval History
What EPRONTIA Treats
5 indicationsEPRONTIA is approved for 5 conditions since its original approval in 2021. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Epilepsy
- Partial-Onset Seizures
- Generalized Tonic-Clonic Seizures
- Lennox-Gastaut Syndrome
- Migraine
Drugs Similar to EPRONTIA
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
EPRONTIA FDA Label Details
ProIndications & Usage
FDA Label (PDF)EPRONTIA is indicated for: Epilepsy: Initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older ; adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older . Preventive treatment of migraine in patients 12 years of age and older . 1.1 Monotherapy Epilepsy EPRONTIA is indicated as initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in ...
EPRONTIA Patents & Exclusivity
Patents (11 active)
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.